---
title: Metabolic Study of Women With Polycystic Ovary Syndrome and Sleep Apnea
nct_id: NCT00696111
overall_status: COMPLETED
phase: NA
sponsor: University of Chicago
study_type: INTERVENTIONAL
primary_condition: Polycystic Ovary Syndrome
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00696111.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00696111"
ct_last_update_post_date: 2024-12-31
last_seen_at: "2026-05-12T06:33:49.485Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Metabolic Study of Women With Polycystic Ovary Syndrome and Sleep Apnea

**Official Title:** PCOS, Sleep Apnea and Metabolic Risk in Women

**NCT ID:** [NCT00696111](https://clinicaltrials.gov/study/NCT00696111)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 18
- **Lead Sponsor:** University of Chicago
- **Collaborators:** Duke University, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- **Conditions:** Polycystic Ovary Syndrome, Obstructive Sleep Apnea
- **Start Date:** 2007-12
- **Completion Date:** 2022-06-30
- **CT.gov Last Update:** 2024-12-31

## Brief Summary

The purpose of this study is to look at the metabolic (use of energy) and hormonal features of sleep problems in women with polycystic ovary syndrome (PCOS).

## Detailed Description

The prevalence of obesity and chronic sleep loss are at record levels among Americans and evidence continues to emerge to support a causal link between the two conditions. Metabolic abnormalities related to sleep disruption are particularly evident in individuals with obstructive sleep apnea (OSA), a disorder traditionally associated with male gender. While more prevalent in men, OSA is underrecognized in women in part because its clinical and polysomnographic features differ from those of men. Women with polycystic ovary syndrome (PCOS) are particularly susceptible to OSA with at least a 5-fold higher risk for its development compared to obese women without PCOS. This study will enroll obese women with PCOS, with and without OSA. Those with OSA will be randomized to receive CPAP or to receive depot leuprolide to suppress ovarian steroid output over 12 weeks, reassessed at 6 weeks, and then randomized (double-blind, placebo controlled) to 6 weeks of either micronized estrogen + placebo or micronized progestin + placebo. The independent effects of androgen, estrogen, and progesterone on OSA and metabolic function will be assessed. In addition, primary human adipocytes will be prepared from fat biopsies obtained from subjects. Insulin sensitivity will be determined by phospho-specific immunoblotting in conjunction with glucose uptake and anti-lipolysis assays. In parallel, adipocytes from these subjects will be cultured for 1-5 days prior to metabolic assays to ascertain if removal of from circulating factors will improve insulin signaling, or if insulin resistance persists in vitro. Finally, there will be an interface with the Metabolomics Laboratory at Duke University (C. Newgard, Lab Director), and metabolomics assessment will be done on blood and urine samples.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 40 Years
- **Sex:** FEMALE
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Clinical diagnosis of PCOS
* Obese (BMI of at least 30 kg/m2)

Exclusion Criteria:

* Diagnosis of nonclassic 21-hydroxylase deficiency, Cushing syndrome, hypothyroidism, or significant elevations in prolactin
* Taking steroid preparations (including oral contraceptives), medications known to alter insulin secretion and/or action, or medications known to influence sleep during the 2 months prior to starting the study
* Positive pregnancy test
* Diagnosis of diabetes mellitus
* Hypertension (systolic \> 140 mmHg and/or diastolic \> 90 mmhg) not well-controlled on stable medication with either ACE inhibitors or diuretics
* Habitual alcohol use
* Excessive caffeine intake of more than 300 mg/day
* Known peanut allergies, or allergies to medications used in the study
* Hemoglobin \< 11g/dL and/or hematocrit \< 33%
* Systemic illnesses, including heart, renal, liver, or malignant disease
```

## Arms

- **Depot Lupron and estrogen plus placebo** (EXPERIMENTAL) — Randomized to receive depot Lupron for 6 weeks. Then randomized again to receive estrogen plus placebo for another 6 weeks.

## Interventions

- **Depot Lupron followed by estrogen plus placebo** (DRUG) — A single intramuscular dose of depot lupron (11.25 mg). Six weeks after injection, subjects will receive daily oral doses of estrogen (2mg) plus placebo for six weeks.

## Primary Outcomes

- **Estrogen Levels** _(time frame: Baseline)_ — Estrogen levels measured every 20 minutes for 24 hours and the the average of those values are presented. The units of measurement are picograms per milliter (pg/ml).
- **Sleep Efficiency Measured at Baseline** _(time frame: Baseline)_ — Sleep efficiency recorded with polysomnography minimum value = 0%, maximum value = 100%, higher values are a better outcome.
- **Total Testosterone** _(time frame: Baseline)_ — Total Testosterone levels measured every 20 minutes for 24 hours and the average of those values are presented. The units of measurement are picograms per milliter (pg/ml).

## Secondary Outcomes

- **Intravenous Glucose Tolerance Test** _(time frame: Baseline)_

## Locations (1)

- University of Chicago Department of Medicine, Section of Endocrinology, Diabetes & Metabolism, Chicago, Illinois, United States

## Recent Field Changes (last 30 days)

- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.university of chicago department of medicine, section of endocrinology, diabetes & metabolism|chicago|illinois|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT00696111.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT00696111*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*